Finance

Beta
Lists
092730:KOSDAQ
NeoPharm Co., Ltd.
₩17,020.00
-0.87%
(-150.00) 1D
Jun 10, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 092730...
Open
₩17,170
High
₩17,280
Low
₩16,510
Mkt. cap
272.80B
Avg. vol.
59.78K
Volume
27.74K
Dividend
4.41%
Quarterly dividend
₩187
Ex-dividend date
Dec 27, 2023
P/E ratio
9.07
52-wk high
₩22,650
52-wk low
₩13,820
EPS
₩1,876
Shares outstanding
16.03M
No. of employees
178
Open
₩17,170
High
₩17,280
Low
₩16,510
Mkt. cap
272.80B
Avg. vol.
59.78K
Volume
27.74K
Dividend
4.41%
Quarterly dividend
₩187
Ex-dividend date
Dec 27, 2023
P/E ratio
9.07
52-wk high
₩22,650
52-wk low
₩13,820
EPS
₩1,876
Shares outstanding
16.03M
No. of employees
178
News stories
From sources across the web
About NeoPharm Co., Ltd.
CEO-
Employees178
Founded2000
Headquarters-
SectorPersonal care products
Websiteneopharm.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
31.61B
31.98B
32.20B
36.40B
Cost of goods sold
10.87B
10.95B
11.64B
12.33B
Cost of revenue
10.87B
10.95B
11.64B
12.33B
Research and development expenses
799.60M
901.99M
865.48M
767.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.76B
12.74B
12.51B
15.59B
Operating expense
12.96B
14.02B
13.78B
16.85B
Total operating expenses
23.83B
24.97B
25.43B
29.18B
Operating income
7.78B
7.01B
6.77B
7.22B
Other non operating income
37.15M
-47.23M
26.63M
10.85M
EBT including unusual items
9.09B
6.23B
8.50B
8.44B
EBT excluding unusual items
9.11B
6.22B
8.43B
8.47B
Income tax expense
1.96B
-840.28M
1.64B
1.68B
Effective tax rate
21.53%
-13.50%
19.30%
19.91%
Other operating expenses
-
-
-
-
Net income
7.14B
7.07B
6.86B
6.76B
Net profit margin
22.58%
22.10%
21.30%
18.57%
Earnings per share
-
-
-
-
Interest and investment income
1.05B
958.72M
890.67M
882.49M
Interest expense
-7.85M
-7.54M
-8.51M
-15.52M
Net interest expenses
1.04B
951.18M
882.15M
866.97M
Depreciation and amortization charges
313.49M
316.66M
359.27M
439.26M
EBITDA
8.55B
7.75B
7.55B
8.08B
Gain or loss from assets sale
19.32M
-6.63M
-72.45M
653.34K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer